News On Women (Free subscription) | 12/01/2009
Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer. Lorianne, who holds an M.D. from the University of California, Davis and completed her fellowship at the Yale School of...
bizjournals (Free subscription) | 11/30/2009
Nektar Therapeutics on Monday announced the promotion of Dr. Lorianne Masuoka to senior vice president and chief medical officer. (NKTR)
PR News Wire (Free subscription) | 11/30/2009
SAN CARLOS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer. Dr. Masuoka will report directly to Nektar's President and Chief Executive Officer, Howard W. Robin.
Red Orbit (Free subscription) | 11/30/2009
SAN CARLOS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer. Dr.
GuruFocus Updates (Free subscription) | 11/05/2009
By 10qk. Nektar Therapeutics ( NKTR ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
PR News Wire (Free subscription) | 11/04/2009
SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2009.
Red Orbit (Free subscription) | 11/04/2009
SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2009.
PR News Wire (Free subscription) | 10/29/2009
SAN CARLOS, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00...
Red Orbit (Free subscription) | 10/29/2009
SAN CARLOS, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of U.S.-based financial markets.
Medical News Today (Free subscription) | 10/29/2009
Nektar Therapeutics (Nasdaq: NKTR) announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
Red Orbit (Free subscription) | 10/11/2009
PHOENIX and SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.
SeekingAlpha.com (Free subscription) | 10/05/2009
Zacks.com submits: Recently, AstraZeneca ( AZN ) entered into a licensing deal with Nektar Therapeutics ( NKTR ) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a Phase II trial for the treatment of opioid-induced constipation, the latter, in early stage of development, is intended to treat pain without constipation side effects. Nektar will receive an upfront...
Business Wire (Free subscription) | 09/23/2009
CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights Skyworks Solutions (SWKS) as the Bull of the Day and Valero Energy (VLO) the Bear of the Day. In addition, Zacks Equity Research provides analysis on AstraZeneca (AZN), Nektar Therapeutics (NKTR) and Wyeth (WYE). Full analysis of all these stocks is available at http://at.zacks.com/?id=2676. Here is a synopsis of all five stocks: Bull of the...
Indian Express (Free subscription) | 09/23/2009
AstraZeneca and US-based Nektar Therapeutics have entered into a worldwide licencing agreement for two drug development programmes, NKTR-118 and NKTR-119.
Fiercebiotech (Free subscription) | 09/22/2009
Yesterday shares of Nektar Therapeutics jumped 13 percent on the news that the developer had struck a $1.5 billion licensing deal for two of its development programs with AstraZeneca. This morning its shares rose 11 percent after investigators said a small, early-stage trial of a new ovarian cancer drug produced promising results. Two of the five patients in the trial of NKTR-102 were evaluable for...
Videos